FDA-approved option for low sexual desire
PT-141 (Bremelanotide)
A melanocortin receptor agonist approved for a specific low sexual desire diagnosis, prescribed by telehealth providers for broader sexual health support.
Overview
PT-141 works through the nervous system rather than the vascular system used by other sexual health medications. It carries an FDA approval for a specific diagnosis, and clinics vary on eligibility criteria and how it fits alongside other options.
